Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

NEWTON, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), presented extended results from its validated research-use plasma pTau217 assay to screen potential participants in the ongoing Phase 2 ALTITUDE-AD clinical trial of sabirnetug, showing this strategy has performed as intended. The company presented the results during an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) in Vienna, Austria, from April 1-5, 2025, and will deliver an encore presentation at the American Academy of Neurology (AAN) Annual Meeting in San Diego, Calif., from April 5-9, 2025. Acumen is also presenting posters on methods of interrogating the binding of AβOs to a model of human neurons, methods to advance Aβ selectivity measurements and early effects of sabirnetug on synaptic biomarkers in AD.

Read more at globenewswire.com